Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we see moves to potentially dismantle FDA ad comms, see the U.S. pressuring the U.K. over its stringent drug-pricing policy, and more.

The need-to-know this morning

Monte Rosa Therapeutics signed a research collaboration agreement with Novartis to develop new treatments for autoimmune diseases based on Monte Rosa’s protein degrader technology.

ATyr Pharma said its experimental drug efzofitimod failed to reduce the use of oral steroids compared to placebo in a Phase 3 study of pulmonary sarcoidosis, a type of inflammatory lung disease.

FDA retreats from expert drug panels

FDA leaders under President Trump are moving to curtail the agen

See Full Page